北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial
作者: Zhu, Hong-Hu1; Wu, De-Pei2; Jin, Jie3; Li, Jian-Yong4; Ma, Jun5; Wang, Jian-Xiang6,7,8; Jiang, Hao1; Chen, Sai-Juan9; Huang, Xiao-Jun1
刊名: JOURNAL OF CLINICAL ONCOLOGY
发表日期: 2013-11-20
DOI: 10.1200/JCO.2013.48.8312
卷: 31, 期:33, 页:4215-+
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: TRANS-RETINOIC ACID ; RISK-ADAPTED TREATMENT ; CLINICAL-EFFICACY ; THERAPY ; CELLS ; PHARMACOKINETICS ; ANTHRACYCLINE ; COMBINATION ; MECHANISMS ; MANAGEMENT
英文摘要:

Purpose This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of an oral tetra-arsenic tetra-sulfide (As4S4) -containing formula named the Realgar-Indigo naturalis formula (RIF) compared with intravenous arsenic trioxide (ATO) as both induction and maintenance therapies for newly diagnosed acute promyelocytic leukemia (APL).

Patients and Methods In all, 242 patients with APL were randomly assigned (1:1) to oral RIF (60 mg/kg) or ATO (0.16 mg/kg) combined with all-trans retinoic acid (ATRA; 25 mg/m(2)) during induction therapy. After achieving complete remission (CR), all patients received three courses of consolidation chemotherapy and maintenance treatment with sequential ATRA followed by either RIF or ATO for 2 years. The primary end point was the rate of disease-free survival (DFS) at 2 years, which was assessed for noninferiority with a 10% noninferiority margin.

Results The median follow-up time was 39 months. DFS at 2 years was 98.1% (106 of 108) in the RIF group and 95.5% (107 of 112) in the ATO group. The DFS difference was 2.6% (95% CI, -3.0% to 8.0%). The lower limit of the 95% CI of DFS difference was greater than the -10% noninferiority margin, confirming noninferiority (P < .001). No significant differences were noted between the RIF and ATO groups with regard to the CR rate (99.1% v 97.2%; P = .62) or the overall survival at 3 years (99.1% v 96.6%; P = .18). The rates of adverse events were similar in the two groups.

Conclusion Oral RIF plus ATRA is not inferior to intravenous ATO plus ATRA as first-line treatment of APL and may be considered as a routine treatment option for appropriate patients.

语种: 英语
所属项目编号: 2006AA02A405 ; 2012AA02A505 ; 2008ZX09312-026 ; Z111107067311070
项目资助者: National High-Tech RD (863) Program ; Mega Project of the Ministry of Science and Technology ; Beijing Municipal Science &amp ; Technology Commission
WOS记录号: WOS:000327088000008
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66292
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Harbin Inst Hematol & Oncol, Harbin, Peoples R China
3.Soochow Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
4.Zhejiang Univ, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
5.Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China
6.Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
7.Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
8.Peking Union Med Coll, Tianjin, Peoples R China
9.Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China

Recommended Citation:
Zhu, Hong-Hu,Wu, De-Pei,Jin, Jie,et al. Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial[J]. JOURNAL OF CLINICAL ONCOLOGY,2013,31(33):4215-+.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhu, Hong-Hu]'s Articles
[Wu, De-Pei]'s Articles
[Jin, Jie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhu, Hong-Hu]‘s Articles
[Wu, De-Pei]‘s Articles
[Jin, Jie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace